Regeneron Pharmaceuticals (REGN) vs Sanofi (SNY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Regeneron Pharmaceuticals (REGN) has outperformed Sanofi (SNY) over the past year, gaining 27.2% versus a loss of 18.3%. Over five years, REGN leads with a +34.1% price change compared with -17.7% for SNY. Sanofi is the larger company by market cap ($95.80 billion vs $74.71 billion), about 1.3 times the size.
On valuation, Sanofi trades at a lower forward P/E (7.4x vs 11.8x for Regeneron Pharmaceuticals). Sanofi offers the higher dividend yield (10.31% vs 0.50%).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | REGN | SNY |
|---|---|---|
| Share price | $725.67 | $39.98 |
| Market cap | $74.71B | $95.80B |
| 1-day change | -2.22% | -0.55% |
| YTD return | -3.85% | -17.04% |
| 1-year return | +27.24% | -18.29% |
| 5-year return | +34.14% | -17.71% |
| P/E ratio (TTM) | 17.94 | 21.04 |
| Forward P/E | 11.80 | 7.40 |
| EPS (TTM) | $40.44 | $1.90 |
| Dividend yield | 0.50% | 10.31% |
| Annual dividend | $3.64 | $4.12 |
| Revenue (latest FY) | $14.34B | — |
| Revenue growth (YoY) | +0.99% | — |
| Net income (latest FY) | $4.50B | — |
| Operating margin | 24.95% | — |
| Net margin | 31.41% | — |
| 52-week high | $859.34 | $52.68 |
| 52-week low | $541.00 | $39.18 |
| Distance from 52-week high | -15.56% | -24.11% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +17.99% | +34.09% |
| Average volume | 739.67K | 2.89M |
| Shares outstanding | 101.14M | 2.40B |
| Employees | 15,410 | 74,846 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- REGN has outperformed SNY by 45.5 percentage points over the past year.
- Sanofi offers a meaningfully higher dividend yield (10.31% vs 0.50%).
About Regeneron Pharmaceuticals
REGN stock →Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide.
Health Care · Biotechnology: Pharmaceutical Preparations · 15,410 employees
About Sanofi
SNY stock →Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines.
Health Care · Biotechnology: Pharmaceutical Preparations · 74,846 employees
REGN vs SNY FAQ
Which is bigger, Regeneron Pharmaceuticals or Sanofi?
Sanofi (SNY) is larger, with a market capitalization of $95.80B compared with $74.71B for Regeneron Pharmaceuticals (REGN).
Which stock has performed better over the past year, REGN or SNY?
REGN returned +27.24% over the past 12 months, compared with -18.29% for SNY (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, REGN or SNY?
REGN has the lower trailing P/E at 17.9, versus 21.0 for SNY. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Regeneron Pharmaceuticals or Sanofi?
Sanofi has the higher yield at 10.31%, compared with 0.50% for Regeneron Pharmaceuticals.
Are Regeneron Pharmaceuticals and Sanofi in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.